SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making waves for acquiring Blueprint for $9.5 billion. Sanofi (NASDAQ:SNY), a ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...

The patient’s grade 4 bullous pemphigoid emerges despite cabozantinib dose reduction, requiring high-dose corticosteroids and ...

Dupixent is a brand-name medication that doctors prescribe to treat eosinophilic esophagitis (EoE). Learn more about how long to receive Dupixent, how it works, and side effects.

The possibility of bullous pemphigoid was also unlikely, given that the blister was located on "a single distal extremity," the researchers said.

As the future of rare disease research at Cincinnati Children's is threatened, parents of 13-year-old Charlie Evans plead for its reinstatement.

Direct immunofluorescence biopsy may be a useful tool in the diagnosis of pediatric patients with potential immune-mediated skin disorders.